Terms: = Thyroid cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
2806 results:
1. Management of Advanced Medullary thyroid Carcinoma: Current Systemic Therapy Options.
Jara MA
Crit Rev Oncog; 2024; 29(3):83-90. PubMed ID: 38683155
[TBL] [Abstract] [Full Text] [Related]
2. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
3. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract] [Full Text] [Related]
4. BRAF and ret polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract] [Full Text] [Related]
5. Correlation Between the Clinicopathological Features of Papillary thyroid Carcinoma Complicated with Hashimoto's thyroiditis, BRAF V600E Gene Mutation, and ret Gene Rearrangement.
Xie M; Xu ZX; Dai M; Zhu YY
J Coll Physicians Surg Pak; 2024 Apr; 34(4):445-450. PubMed ID: 38576288
[TBL] [Abstract] [Full Text] [Related]
6. Advances in targeted therapy and biomarker research in thyroid cancer.
Guo M; Sun Y; Wei Y; Xu J; Zhang C
Front Endocrinol (Lausanne); 2024; 15():1372553. PubMed ID: 38501105
[TBL] [Abstract] [Full Text] [Related]
7. Accelerated men2a in homozygous ret carriers in the context of consanguinity.
Machens A; Dralle H
Eur J Endocrinol; 2024 Mar; 190(3):K43-K46. PubMed ID: 38465999
[TBL] [Abstract] [Full Text] [Related]
8. [Stratified application of gene expression in diagnosis of thyroid nodules].
Guan WY; Zheng JY; Nie L; Wu HY
Zhonghua Bing Li Xue Za Zhi; 2024 Mar; 53(3):264-268. PubMed ID: 38433054
[No Abstract] [Full Text] [Related]
9. Generating Potential ret-Specific Inhibitors Using a Novel LSTM Encoder-Decoder Model.
Liu L; Zhao X; Huang X
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397034
[TBL] [Abstract] [Full Text] [Related]
10. The role of prophylactic parathyroidectomy during thyroidectomy for MTC in patients with men2a syndrome.
Kavazis C; Romanidis K; Pitiakoudis M; Kesisoglou I; Laskou S; Sapalidis K
Folia Med (Plovdiv); 2023 Oct; 65(5):720-727. PubMed ID: 38351753
[TBL] [Abstract] [Full Text] [Related]
11. ret kinase inhibitors for the treatment of ret-altered thyroid cancers: Current knowledge and future directions.
Hamidi S; Hu MI
Ann Endocrinol (Paris); 2024 Apr; 85(2):118-126. PubMed ID: 38342224
[TBL] [Abstract] [Full Text] [Related]
12. The Pathogenic ret Val804Met Variant in Acromegaly: A New Clinical Phenotype?
Chiloiro S; Capoluongo ED; Costanza F; Minucci A; Giampietro A; Infante A; Milardi D; Ricciardi Tenore C; De Bonis M; Gaudino S; Rindi G; Olivi A; De Marinis L; Pontecorvi A; Doglietto F; Bianchi A
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339173
[TBL] [Abstract] [Full Text] [Related]
13. Integrated budget impact model to estimate the impact of introducing selpercatinib as a tumor-agnostic treatment option for patients with
Bhandari NR; Gilligan AM; Myers J; Ale-Ali A; Smolen L
J Med Econ; 2024; 27(1):348-358. PubMed ID: 38334069
[TBL] [Abstract] [Full Text] [Related]
14. Updates on the genetics of multiple endocrine neoplasia.
Sahakian N; Castinetti F; Romanet P; Reznik Y; Brue T
Ann Endocrinol (Paris); 2024 Apr; 85(2):127-135. PubMed ID: 38325596
[TBL] [Abstract] [Full Text] [Related]
15. thyroid cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract] [Full Text] [Related]
16. [Intestinal ganglioneuromatosis as an early extra-endocrine manifestation of type 2B multiple endocrine neoplasia].
Averianova JV; Kalinchenko NY; Brovin DN; Petryaykina EE; Tiulpakov AN
Probl Endokrinol (Mosk); 2023 Jun; 69(6):109-112. PubMed ID: 38312000
[TBL] [Abstract] [Full Text] [Related]
17. [A Case Report of Multiple Endocrine Neoplasia Type 2A(men2a)Diagnosed with Medullary thyroid Carcinoma].
Morikawa N; Yoshitomi S; Shimabara M; Tatara N; Hara K; Ikeda E; Tsuji H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1780-1782. PubMed ID: 38303205
[TBL] [Abstract] [Full Text] [Related]
18. Clinical value of multi-gene testing in distinguishing benign and malignant thyroid nodules.
Zhang M; Hu X; Liu L; Wang Y; Jiang J; Li H; Fei W; Zhong T; Jiang Z
Medicine (Baltimore); 2024 Jan; 103(4):e35960. PubMed ID: 38277563
[TBL] [Abstract] [Full Text] [Related]
19. Extent of Surgery for Medullary thyroid cancer and Prevalence of Occult Contralateral Foci.
Mao YV; Hughes EG; Steinmetz D; Troob S; Kim J; Tseng CH; Fishbein GA; Sajed DP; Livhits MJ; Yeh MW; Lee D; Angell TE; Wu JX
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):209-214. PubMed ID: 38270925
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of pralsetinib in Chinese advanced ret-mutant medullary thyroid cancer patients.
Zheng X; Fang M; Fan Y; Sun Y; Sun M; Yang A; Zhang B; Liu Q; Liu H; Zhou X; Huang T; Qin J; Wang Z; Qin M; Shen Z; Yao S; Yang J; Wang Y; Gao M
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38261313
[TBL] [Abstract] [Full Text] [Related]
[Next]
